Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases
ConclusionsIn our series of patients with NSCLC and brain metastases treated with pembrolizumab, IRAE presence was associated with a significant increase in OS, systemic TTF, and intracranial TTF. Future studies with increased cohorts will clarify how IRAEs should be interpreted among molecular subtypes.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Study